{"slug":"vip-gabapentin","verification":{"valid":true,"entries":1,"head":"de3b5d999b5e5ec6bfb3f880d14fb203c0ca4b0f380580d8c934807f587e5445"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.040916,"waste_cost_usd":0,"total_tokens":29423,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.040916,"tokens_total":29423,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:31:55.176Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP Peptide Evidence for Gabapentin Users: Immune and Autonomic Layers","register":"source_ledger","body":"## What's breaking down if you have Gabapentin / pregabalin\n\nGabapentin and pregabalin primarily act on voltage-gated calcium channels to reduce excitatory neurotransmitter release. This leads to dampened nerve signaling in conditions involving neuropathic pain or hyperexcitability. The drug suppresses pain signals without addressing underlying nerve tissue integrity or inflammatory states that may contribute to ongoing issues. If autonomic regulation or immune balance plays a role in your experience with these medications, that layer remains unaddressed by the drug itself.\n\nDegeneration here centers on sustained nerve hyperexcitability and potential secondary inflammatory contributions rather than direct mechanical breakdown. Repair pathways would focus on modulating immune responses and autonomic tone to support tissue homeostasis instead of ongoing signal suppression.\n\n## Why VIP might help you\n\n1. You are reading about Gabapentin / pregabalin — what breaks down matters before any compound name.\n2. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nVIP acts on VPAC1 and VPAC2 receptors expressed in immune cells and autonomic nerves. This binding can shift cytokine profiles toward lower pro-inflammatory markers in lab models. If your situation involves immune overactivation alongside nerve signaling changes addressed by gabapentin, VIP's receptor activity offers a distinct path focused on restoring balance rather than blocking calcium influx.\n\nIn this framing, VIP supports autonomic nerve function through vasodilation and smooth muscle regulation observed in multiple tissue types. The result could complement signal suppression by addressing a separate layer of tissue-level regulation.\n\n## Why Gabapentin / pregabalin matters for you\n\nDrug: Gabapentin / pregabalin\nWhat it does: Masks neuropathic pain signal; does not repair nerve.\nTherefore for you: This drug suppresses a signal. Suppression can reduce immediate load on daily function but trades off against repair by leaving the underlying nerve and immune environment unchanged. Long-term reliance on signal masking may allow degenerative processes in those layers to continue unchecked.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\nVIP's immune and autonomic actions address a layer separate from gabapentin's calcium channel effects. The combination in principle allows signal reduction while supporting repair-oriented modulation. No overlapping mechanisms are claimed here.\n\n## What the evidence actually shows\n\nPreclinical studies in mice demonstrate VIP reduces incidence and severity of collagen-induced arthritis through suppression of inflammatory mediators (source s5 from web:5 and web:12). This is an animal model of autoimmune joint inflammation, not neuropathic pain or gabapentin use. Human data on VIP for similar immune layers remain limited to observational or small infusion studies unrelated to gabapentin.\n\nA randomized clinical trial in healthy volunteers tested VIP infusion for headache provocation and found modest effects on cranial hemodynamics (source s11 from web:11). This human study does not address gabapentin users or nerve repair.\n\nOne human study measured lower VIP levels in patients with primary pulmonary hypertension compared to controls (source s16 from web:16). This is mechanistic observation, not a trial of VIP administration for pain or gabapentin contexts.\n\nNo human trials directly examine VIP alongside gabapentin or pregabalin. Claims linking the two remain mechanistic or speculative.\n\n## What scientists say\n\nReviews describe VIP as a neuropeptide with anti-inflammatory and immunomodulatory properties in preclinical settings, including regulation of NF-κB signaling (source s6 from web:6 and web:14). Researchers note potential neuroprotective roles in peripheral nerves from rat injury models (source s13 from web:13). Scientists emphasize that translation to human neuropathic conditions requires further clinical work.\n\n## What people say on Reddit\n\nAnecdotal reports mention VIP in contexts of nervous system calming or sleep support, sometimes alongside discussions of gabapentin reduction via other interventions (source s20 from web:20). One thread notes VIP peptide use for overall nervous system balance in users managing chronic symptoms (source s18 from web:18). These are user experiences, not controlled data, and do not establish cause-effect with gabapentin.\n\n## What people say on X\n\nPosts focus on gabapentin and pregabalin mechanisms as calcium channel inhibitors without GABA receptor binding (source s28 from post:28). Other posts discuss side effect concerns or off-label use but contain no references to VIP peptide (source s31 from post:31). No direct user anecdotes connect VIP to gabapentin on the platform in searched results.\n\n## What we do not know\n\nHuman evidence for VIP specifically in gabapentin or pregabalin users is absent. Long-term effects on nerve regeneration or interaction with calcium channel modulation remain unstudied in controlled settings. Autonomic or immune benefits observed in other models have not been tested against the suppression profile of these drugs.\n\n## Safety and limits\n\nVIP research includes infusion studies in healthy volunteers showing hemodynamic changes (source s2 from web:2). Broader safety data for compounded or research-use VIP derive from observational contexts rather than large trials. Any consideration of layering compounds with existing medications requires individualized medical oversight. Evidence grading here separates clear preclinical immune modulation from the lack of direct human data on this specific cross.","claims":[{"id":"c1","text":"VIP reduces incidence and severity of collagen-induced arthritis in mice via inflammatory mediator suppression.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Establishes preclinical immune modulation layer separate from pain signal suppression.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:54.631Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"A randomized trial showed VIP infusion produces modest cranial hemodynamic effects in healthy volunteers.","section":"What the evidence actually shows","tier":"human","source_ids":["s11"],"source_status":"sourced","why_material":"Provides the main human trial data point on VIP administration.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:54.631Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Lower VIP levels observed in primary pulmonary hypertension patients versus controls.","section":"What the evidence actually shows","tier":"human","source_ids":["s16"],"source_status":"sourced","why_material":"Mechanistic observation of VIP in a disease state.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:54.631Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Gabapentin and pregabalin inhibit α2δ subunit-containing voltage-dependent calcium channels.","section":"Why Gabapentin / pregabalin matters for you","tier":"mechanistic","source_ids":["s28"],"source_status":"sourced","why_material":"Confirms signal suppression mechanism without repair.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:54.631Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP shows anti-inflammatory effects in mouse arthritis models but no direct human neuropathic pain trials exist.","section":"What we do not know","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Highlights evidence gap for the specific cross.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:31:54.631Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s5","type":"review","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"Vasoactive intestinal peptide (VIP) prevents experimental arthritis","quote":"Mice treated with VIP showed delayed onset, lower incidence and decreased severity of CIA in comparison with placebo-treated arthritic mice.","link_status":"ok","quote_status":"verified"},{"id":"s11","type":"clinical_trial","url":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782759","title":"Effect of Vasoactive Intestinal Polypeptide on Development of Headache and Associated Symptoms","quote":"This randomized clinical trial examines whether a 2-hour infusion of vasoactive intestinal polypeptide provokes migraine attacks.","link_status":"http_403","quote_status":"unverified"},{"id":"s16","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"VIP level in normal subjects (n = 45) was 42.4 ± 17.1 pg/ml. ... VIP levels in the group of PPH patients (n = 12) were at the detection threshold of the assay (i.e., 10 pg/ml).","link_status":"ok","quote_status":"unverified"},{"id":"s28","type":"other","url":"https://x.com/PharmaFactz/status/1176592633847844870","title":"Mechanism of Pregabalin / Gabapentin","quote":"both drugs act as inhibitors of α2δ subunit-containing voltage-dependent calcium channels (VDCCs).","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":26113,"tokens_out":3310,"cost":0.04091625,"prev_hash":"genesis","hash":"de3b5d999b5e5ec6bfb3f880d14fb203c0ca4b0f380580d8c934807f587e5445"}]}